In the future, exploring the association between IGF-1 levels and the risk of NAFLD in a broader demographic could validate the necessity for IGF-1 level screening in populations vulnerable to NAFLD, potentially leading to more precise identification of individuals at increased risk for the condition. The gene discussed is IGF1; the disease is metabolic dysfunction-associated steatotic liver disease.